

Media Contact:

Jackie Hanley
Racepoint Group
781-487-4625

jhanley@racepointgroup.com

Proventys to Unveil Clinical Research Evaluating Its Predictive Technology Platform at 2009 American Medical Informatics Association Spring Congress

Poster Presentations Explore Value and Efficiency of Clinical Decision Support Software and Embedded Multivariate Predictive Model in Enhancing Patient Care

DURHAM, N.C., May 21, 2009 — Proventys Inc., a healthcare technology company committed to advancing personalized medicine through predictive solutions delivered at the point of care, announced today that the company will be presenting two posters at the 2009 American Medical Informatics Association (AMIA) Spring Congress to be held on May 28-30 in Orlando, Fla. The company's two scientific poster presentations are titled "Usability of a Risk Prediction Platform for Clinical Decision Support," and "Accuracy of Clinicians versus Multivariable Model in Predicting Chemotherapy-Induced Febrile Neutropenia." Members of the Proventys research team will deliver the presentations, including Hank Head, Chris Leithe, Surya Singh, M.D., Jason Langheier, and Yang Wu, Ph.D.

The first poster presentation focuses on the process of User Centered Design (UCD) and progressive usability testing utilized by the researchers to design an effective and user-friendly clinical decision support software (CDSS) system for clinicians. While adoption of CDSS can be delayed or halted by issues such as repetitive or clinically irrelevant alerts, the UCD and testing system employed by the Proventys research team has led to the engagement of end-users throughout the development process, preventing the occurrence of many of these issues. In addition, oncologists' involvement in the early stages of the CDSS design process has contributed to the identification and mitigation of potential risks to patient safety.

The second presentation focuses on personalized risk assessment as a key component for the successful implementation of prospective health care. The research team will present the results of a study comparing oncologists' assessment of patients' risk of chemotherapy-

induced neutropenic events with that of a validated, multivariate predictive model. Key findings include significant discordance between the risk assessments. Combined with the previously described predictive accuracy of the model, these results suggest that the model has the potential to decrease the incidence of febrile neutropenia by providing more objective and patient specific decision criteria for risk assessment. In turn, this would ultimately lead to better patient outcomes and an increased emphasis on individualized treatments.

Additional details are as follows:

- **Who:** Hank Head, Chris Leithe, Surya Singh, M.D., Jason Langheier and Yang Wu, Ph.D.
- **What:** 2009 AMIA Spring Congress Poster Presentations - titled “Usability of a Risk Prediction Platform for Clinical Decision Support,” and “Accuracy of Clinicians versus Multivariate Model in Predicting Chemotherapy-Induced Febrile Neutropenia”
- **When:** May 30, 2009
- **Where:** Walt Disney World Swan, Orlando, Fla.

About Proventys

Based in Durham, NC and Boston, MA, Proventys is a healthcare technology company committed to advancing personalized medicine through predictive solutions delivered at the point of care. The company’s proprietary web-based platform, the Proventys PDx System™ is a novel, standalone software system that leverages validated risk models and other predictive technologies in an effort to help clinicians make complex treatment decisions personalized to the patient across a range of disease conditions. Proventys has relationships with leading researchers in oncology, cardiovascular disease and other areas, and a strategic partnership with McKesson Corporation. By helping clinicians predict patient outcomes and guiding appropriate care decisions, Proventys is enabling a more prospective, personalized approach to healthcare. For more information, visit www.proventys.com.

###

